Fidaxomicin has shown promise as an effective treatment option for Clostridium difficile infections, but no pharmacoeconomic studies have been performed to date.
Jason W. Lancaster, PharmD, BCPS
Advertisement
Articles by Jason W. Lancaster, PharmD, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5